An engineered micropattern to reduce bacterial colonization, platelet adhesion and fibrin sheath formation for improved biocompatibility of central venous catheters by unknown
May et al. Clinical and Translational Medicine  (2015) 4:9 
DOI 10.1186/s40169-015-0050-9RESEARCH Open AccessAn engineered micropattern to reduce bacterial
colonization, platelet adhesion and fibrin sheath
formation for improved biocompatibility of
central venous catheters
Rhea M May1, Chelsea M Magin1, Ethan E Mann1, Michael C Drinker1, John C Fraser1, Christopher A Siedlecki2,
Anthony B Brennan3 and Shravanthi T Reddy1*Abstract
Background: Catheter-related bloodstream infections (CRBSIs) and catheter-related thrombosis (CRT) are common
complications of central venous catheters (CVC), which are used to monitor patient health and deliver medications.
CVCs are subject to protein adsorption and platelet adhesion as well as colonization by the natural skin flora
(i.e. Staphylococcus aureus and Staphylococcus epidermidis). Antimicrobial and antithrombotic drugs can prevent infections
and thrombosis-related complications, but have associated resistance and safety risks. Surface topographies have shown
promise in limiting platelet and bacterial adhesion, so it was hypothesized that an engineered Sharklet micropattern,
inspired by shark-skin, may provide a combined approach as it has wide reaching anti-fouling capabilities. To assess the
feasibility for this micropattern to improve CVC-related healthcare outcomes, bacterial colonization and platelet interactions
were analyzed in vitro on a material common for vascular access devices.
Methods: To evaluate bacterial inhibition after simulated vascular exposure, micropatterned thermoplastic polyurethane
surfaces were preconditioned with blood proteins in vitro then subjected to a bacterial challenge for 1 and 18 h.
Platelet adhesion was assessed with fluorescent microscopy after incubation of the surfaces with platelet-rich
plasma (PRP) supplemented with calcium. Platelet activation was further assessed by monitoring fibrin formation
with fluorescent microscopy after exposure of the surfaces to platelet-rich plasma (PRP) supplemented with calcium in
a flow-cell. Results are reported as percent reductions and significance is based on t-tests and ANOVA models of log
reductions. All experiments were replicated at least three times.
Results: Blood and serum conditioned micropatterned surfaces reduced 18 h S. aureus and S. epidermidis colonization
by 70% (p≤ 0.05) and 71% (p < 0.01), respectively, when compared to preconditioned unpatterned controls.
Additionally, platelet adhesion and fibrin sheath formation were reduced by 86% and 80% (p < 0.05), respectively,
on the micropattern, when compared to controls.
Conclusions: The Sharklet micropattern, in a CVC-relevant thermoplastic polyurethane, significantly reduced
bacterial colonization and relevant platelet interactions after simulated vascular exposure. These results suggest
that the incorporation of the Sharklet micropattern on the surface of a CVC may inhibit the initial events that
lead to CRBSI and CRT.
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Approximately six million central venous catheters
(CVCs) are inserted each year in the U.S. [1] to pro-
vide efficient vascular monitoring and medication de-
livery. Thermoplastic polyurethane (TPU) has been
adopted as the material of choice for CVCs due to its
workability, resiliency and improved blood compatibil-
ity over other plastics [2]. CVC design improvements,
such as valves and cuffs, have been introduced to pre-
vent tube occlusion and limit microbial access to the
bloodstream. Unfortunately even with these improve-
ments, CVCs lead to the downstream complications of
catheter-related blood stream infections (CRBSIs) and
thrombosis (CRT), which are associated with in-
creased mortality [3,4].
CRBSIs are primarily caused by the patient’s skin flora
(e.g. Staphylococcus aureus, S. epidermidis, Candida
spp.) that colonize the device and enter the blood stream
[5]. Education for personnel who insert catheters, use of
sterile barrier precautions, and chlorhexidine skin
antisepsis during insertion have helped to reduce, but
not eliminate, CRBSI rates [1,6,7]. Antimicrobial cath-
eters also show promise in reducing CRBSI rates [8].
However, studies show that these catheters harbor mi-
croorganisms [9] and this constant exposure contrib-
utes to the rise in antimicrobial resistance among
pathogens [10,11].
Factors that lead to thrombus formation and subse-
quent CRT involve a complex series of events beginning
with the deposition of a variety of blood proteins and
tissue factors that together facilitate platelet adhesion to
a surface [12,13]. Platelets then activate and expedite the
coagulation cascade, frequently leading to fibrin sheath
formation along the device within 24 h [14]. Routine
anticoagulation prophylaxis, blood-thinning therapy, and
flushing of catheter ports, typically with heparin, are the
only methods currently used to prevent CRT. Unfortu-
nately, these treatments have not demonstrated efficacy
against morbidity and mortality [14,15] and can lead to
thrombocytopenia, where low platelet counts in the
blood can cause hemorrhaging or an increased risk of
CRT [16,17].
Several studies indicate that infection and thrombosis
are clinically linked where patients with CRBSI often ac-
quire CRT, and vice versa [18-23]. Controlled in vivo
and in vitro studies have demonstrated that fibrin sheath
on catheters increase bacterial colonization and correlate
with positive blood cultures [24-27]. Alternatively, many
bacterial strains, in addition to coagulase-positive S. aur-
eus, can initiate the coagulation cascade resulting in fi-
brin clot formation [28,29]. These studies suggest that
bacterial attachment or fibrin sheath formation on the
surface of CVCs could be an underlying mechanism be-
hind this strong clinical correlation.Incorporation of nano and micropatterns into CVC
surfaces has been proposed to reduce CRBSI and CRT
rates without antimicrobial or antithrombogenic coat-
ings. Specifically, ordered pillar topographies, with di-
mensions of 300 nm to 1 μm, have been shown to
reduce platelet adhesion and aggregation [30,31]. The
Sharklet micropattern, either with recessed (−3SK2×2)
or protruding (+3SK2×2) features on the same size scale
(i.e. 2 μm to 16 μm) contains an ordered arrangement of
features bio-inspired by the diamond-like structure of
shark skin. Sharklet micropatterns have been shown to
control the bioadhesion of a wide range of marine mi-
croorganisms, pathogenic bacteria and eukaryotic cells
[32-37]. The aim of the present study is to expand our
understanding of the performance of the Sharklet micro-
pattern against common microorganisms that cause
CRBSIs after blood protein exposure as well as platelet




Thermoplastic polyurethane (TPU) samples, with and
without the Sharklet micropattern, were created by ther-
mal embossing. Briefly, Tecoflex EG-85A pellets (Lubrizol)
were heated and pressed in a Carver hydraulic press at
185°C and 40 MPa for 10 min to create a blank film. The
resulting film was then embossed against a patterned or
polished (smooth, unpatterned) nickel mold [34] to a thick-
ness of ~0.4 mm in a Carver hydraulic press at 185°C and
40 MPa for an additional 2 min. Each flat 0.4 mm thick
film was either punched into 12 mm diameter circular cou-
pons or cut into 75 × 25 mm rectangles. The micropat-
terns produced by this technique were comprised of
discontinuous channel features arranged in a Sharklet
micropattern that either protruded (+) from or were
recessed (−) into the polymer surface with features 3 μm
tall or deep that were 2 μm wide and spaced by 2 μm; re-
ferred to throughout this study as +3SK2×2 and-3SK2×2
(Figure 1).
Microbial strains, media, and growth conditions
Clinical isolates of S. aureus (ATCC 6538) and S. epi-
dermidis (ATCC 35984) were analyzed in this study. A
single colony of each bacterial strain, plated on tryptic
soy agar (TSA; Criterion), was used to inoculate tryptic
soy broth (TSB; Criterion) and grown in a shaking in-
cubator at 37°C and 280 rpm overnight. Overnight mi-
crobial cultures were sub-cultured and grown to early
log phase in TSB before centrifuging aliquots and resus-
pending cell pellets with 1× phosphate buffered saline
(PBS; CulGeneX) to the desired inoculum concentration
based on a previously-established ratio of optical density
and CFU/ml.
Figure 1 Confocal microscopy images of a) unpatterned controls b)-3SK2x2 and c) +3SK2x2 Sharklet micropatterns replicated in TPU.
Representative images of the surfaces analyzed in this study. Scale bar, 20 μm.
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pre-treatment
Bacterial aggregation, cell death, and clotting occurs when
simultaneously incubating blood with S. aureus [38-42].
For in vitro studies, methods for surface pre-conditioning
with blood or 25% serum, the physiologically relevant
serum concentration found in blood, prior to bacterial in-
oculation were selected based on several published studies
investigating the in vitro effects of blood-bacteria interac-
tions for CVC applications [43-45]. Two agitation states
were investigated as a CVC is subjected to a range of shear
forces from static environments inside the lumen to flow
rates of 17–81 ml/min in the blood vessel, depending on
the tube size [46]. Micropatterned and unpatterned
12 mm TPU coupons (n=4) were pressed to the bottom of
a sterile Petri dish around the outer perimeter. Coupons
were immersed in either citrate-treated whole blood (Bon-
fils Blood Bank) or 25% serum in PBS (Interstate Blood
Bank) for 2 h at 37°C either statically or dynamically
(30 rpm) to match the inoculation condition. The pre-
treatment media was rinsed three times by adding 20 ml
of sterile PBS to the dish, swirling (80 rpm) for 30 s on an
orbital shaker, and decanting the rinsate. Surfaces were
then immersed in 20 ml of inoculum containing ~107
(static) or ~108 (dynamic) CFU/ml of either S. aureus or
S. epidermidis and statically or dynamically incubated for
1 and 18 h at 37°C. After incubation, the inoculum sus-
pension was decanted, surfaces were rinsed three times
identically as washing following pre-treatment, punched
with an 8 mm biopsy punch, vortexed and sonicated as
described above. Bacterial eluate solutions were enumer-
ated by a 10-fold dilution series, plating each dilution onto
TSA, and counting the colony forming units (CFU) after
sufficient growth at 37°C overnight. Each CFU per surface
data point was log10 transformed before statistical analysis.
Each experiment was replicated three times. Fluorescent
microscopy was used to qualitatively verify the 18 h CFU
results by fixing with 4% paraformaldehyde and staining
with TOTO®-3. Images were obtained in three pre-
selected sites per surface by confocal laser scanning mi-
croscopy (Zeiss LSM 510 META on Axiovert 200 M).Platelet adhesion
Micropatterned and unpatterned 12 mm TPU coupons
(n=3) were pressed to the bottom of a sterile Petri dish
around the outer perimeter. Surfaces were immersed in
20 ml of a final concentration of ~106 platelets/μl de-
rived from platelet rich plasma (Bonfils Blood Bank) di-
luted with PBS supplemented with 10 mM calcium
chloride for 2 h 37°C while rotating at 80 rpm. Surfaces
were rinsed three times by adding PBS to the dish, ro-
tating (80 rpm) for 30 s on an orbital shaker, and
decanting the rinsate. Platelets were fixed on surfaces
for 1 h in 1% paraformaldehyde at room temperature.
Fixed surfaces were blocked with 10% normal goat
serum (Invitrogen) for 1 h before applying a primary
αIIbβ3 integrin antibody (ab662, abcam) diluted 1:1000
in 10% normal goat serum (Invitrogen) and incubating
overnight at 4°C. Surfaces were exchange rinsed with
PBS five times before adding secondary Alexa-Fluor-
555 IgG antibody (Invitrogen) diluted 1:100 in 6% nor-
mal goat serum for 1 h at room temperature. Images
were taken in 10 pre-determined locations per sample
by fluorescent microscopy (Zeiss LSM 510 META on
Axiovert 200 M), area coverage (μm2) was measured
using ImageJ, and each coverage data point was log
transformed prior to statistical analysis. Each experi-
ment was replicated four times.
Fibrin sheath formation
Micropatterned and unpatterned 75 × 25 mm TPU sam-
ples were loaded into a two-chamber flow cell and
exposed to a final concentration of ~105 platelets/μl de-
rived from platelet rich plasma (Bonfils Blood Bank) di-
luted in PBS supplemented with 5 mM calcium chloride
at a physiologically relevant flow rate of 100 s−1 for 1 h
at 37°C. Surfaces were rinsed in PBS and fixed with 1%
paraformaldehyde for 1 h at room temperature. Two
14 mm circular samples were cut from each surface and
blocked with 5% goat serum for 1 h prior to staining for
fibrinogen with a goat polyclonal primary antibody
(ab6666, abcam) for 1 h at room temperature. The pri-
mary antibody solution was then exchanged with 5%
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ondary Alexa-Fluor 647 IgG antibody (ab150131, abcam)
in 6% goat serum for 1 h. Images were taken in nine
pre-determined locations per surface by fluorescent mi-
croscopy (Olympus BX3-CBH), area coverage (μm2) was
measured using ImageJ, and each coverage data point
was log transformed prior to statistical analysis. Each ex-
periment was replicated three times.
Statistical analysis
A log reduction (LR) per experiment was calculated by
subtracting the average of the log10 transformed values
from micropatterned surfaces from the average of the
log10 transformed values from unpatterned surfaces.
After confirming the normality of the log reductions by
residual and normal probability plots, the mean log re-
duction was interpreted as the median percent reduction
with the equation: 1-10(-LR). Statistical significance of the
reductions were assessed using a 1-sided t-test of log re-
ductions compared to zero. Estimates of variances and
Tukey tests were assessed using an ANOVA model of
the log transformed data for each unpatterned control
sample and micropatterned sample, with a random effect
for experiment [47]. All analyses were performed using
the statistical software MiniTab16.
Results
Staphylococcal colonization post blood protein pre-
treatment
In the range of environments selected to model the clin-
ical environment, the-3SK2×2 TPU surfaces demon-
strated significant reductions of S. aureus colonization
ranging from 63% to 70% compared to unpatterned
TPU controls, after whole blood pre-conditioning underTable 1 The Sharklet micropattern reduces bacterial coloniza
determination of Average LogCFU/50 mm2; SEM: Standard er













S. epidermidis ATCC 35984 Static 1 Saline
25% Serum
18 Saline
25% Serumdynamic and static conditions (Table 1). The ability of
the Sharklet micropattern to reduce S. aureus colonization
was independent of the presence of flow, incubation time
and pre-treatment media, based on a Tukey simultaneous
test to evaluate significant differences among log reduc-
tions (Table 1). S. epidermidis attachment to challenge
TPU surfaces was below the level of CFU detection when
evaluated after whole blood pre-conditioning or under dy-
namic conditions, similar to previous observations [48].
Thus, 25% serum pre-treatment (a physiologically relevant
concentration of blood proteins) with static incubation
was the only condition that could be quantitatively evalu-
ated (Table 1).-3SK2×2 TPU surfaces demonstrated reduc-
tions of S. epidermidis colonization after 18 h by at least
71% (p < 0.01) when compared to unpatterned TPU con-
trols under both saline and serum pre-conditioning
(Table 1). The capability of the Sharklet micropattern to
reduce S. epidermidis colonization was independent of
conditions, i.e. pre-treatment media and inoculation dur-
ation, based on a Tukey simultaneous test to evaluate sig-
nificant differences among log reductions (Table 1). Since
quantitative results could not be achieved with S. epider-
midis after whole blood pre-conditioning, microscopy was
conducted to determine whether the Sharklet micropat-
tern would perform in this condition. Micrographs quali-
tatively demonstrate Sharklet inhibition of S. aureus and
S. epidermidis with whole blood pre-conditioning after
18 h of incubation (Figure 2). An additional Sharklet
micropattern (+3SK2×2), in which the features protrude
from the surface, was qualitatively assessed for per-
formance as an alternative pattern for a CVC applica-
tion that may be investigated further in future testing. Both
micropatterns demonstrated less microbial colonization
and smaller aggregates than control surfaces for the twotion after blood protein treatment LD: ANOVA








4.05 (0.17) 3.17 (0.20) 94% 0.001 A
A3.82 (0.13) 3.37 (0.16) 83% 0.003
4.91 (0.25) 3.91 (0.21) 89% 0.019 A
3.71 (0.29) 3.23 (0.31) 70% 0.048 A
5.23 (0.22) 4.79 (0.16) 64% 0.128 A
4.5 (0.21) 3.9 (0.37) 74% 0.128 A
5.66 (0.1) 4.82 (0.19) 85% 0.008 A
4.49 (0.17) 4.06 (0.23) 63% 0.032 A
5.04 (0.09) 4.23 (0.15) 84% 0.065 A
3.68 (0.08) 3.24 (0.12) 64% 0.005 A
5.06 (0.1) 3.92 (0.1) 91% 0.001 A
3.84 (0.09) 3.47 (0.12) 71% 0.003 A
Figure 2 The Sharklet micropattern reduces the colonization of
two common CRBSI-associated pathogens after preconditioning
with whole blood. Representative images of unpatterned, +3SK2x2
and-3SK2x2 TPU surfaces colonized for 18 h with S. epidermidis (top
panels) and S. aureus (bottom panels). These qualitative images support
the quantitative results in Table 1. Scale bar, 10 μm.
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were consistently observed on smooth surfaces (Figure 2).
Platelet adhesion
The first step to reducing the potential for device as-
sociated thrombosis is to reduce the level of platelet
adhesion to the device. To investigate the potential of
the Sharklet micropattern to influence platelet adhe-
sion, −3SK2×2 and +3SK2×2 TPU surfaces were evalu-
ated. Representative images and quantitative analysis
show that these surface modifications demonstrated a
76% and 86% (p < 0.05) reduction in platelet area
coverage, respectively, when compared to unpatterned
TPU controls (Figure 3). The difference in adhesion
levels between the two pattern types was not statisti-
cally significant (p=0.21; Figure 3d).
Fibrin sheath formation
An ideal blood contacting biomaterial would reduce both
platelet adhesion and activation to inhibit thromboticFigure 3 The Sharklet micropattern reduces platelet adhesion. Repres
(b) +3SK2x2 and (c) -3SK2x2 TPU surfaces. Quantification of fluorescent ima
platelet area coverage compared to unpatterned controls. Scale bar, 10 μmactivity. To determine whether the Sharklet micropattern
would influence platelet activation in addition to at-
tachment, fibrin sheath formation was measured as a
clinically relevant end-point. The-3SK2×2 and
+3SK2×2 micropatterns in TPU were evaluated and
compared to unpatterned TPU controls. Results show
70% and 80% reductions (p < 0.05) in fibrinogen cover-
age, respectively (Figure 4). The representative images
highlight the differences in fibrin strand formation and
coverage on the unpatterned TPU surface compared to
the distribution of globular fibrinogen on the micropat-
terned surfaces (Figure 4). The +3SK2×2 micropattern
showed significantly lower fibrin sheath coverage than
the-3SK2×2 micropattern across experiments (Tukey
test p = 0.05, Figure 4d).Discussion
Current antimicrobial and heparin coatings used to pre-
vent CRBSI and CRT are limited in their efficacy and are
hampered by safety concerns. Micropatterned surfaces
have shown promise for reducing bioadhesion in a range
of environments and represent a paradigm shift in
methods for improving biomaterial compatibility [49-51].
Ordered pillar or well feature configurations have been
the primary surface topography evaluated for platelet and
bacterial control [30,31,52-58]. However, the Sharklet
micropattern has been shown to be the most effective top-
ography for bacterial control with one to three log reduc-
tions in microbial attachment across a range of species
that cause hospital acquired infections (i.e. Pseudomonas
aeruginosa, Staphylococcus aureus, Escherichia coli, Kleb-
siella pneumoniae, Acinetobacter baumannii) [32-34]. The
true clinical effect of the Sharklet micropattern is the
focus of future investigations based on the promising re-
sults of in vitro studies such as those presented here. The
value of the micropattern approach is the potential to
limit bacterial load below a clinically-relevant level with-
out killing bacteria, so as to avoid the emergence of resist-
ant strains of bacteria and difficult-to-treat infections.entative images of immunostained platelets on (a) unpatterned,
ges revealed that both Sharklet micropatterns significantly reduce
.
Figure 4 The Sharklet micropattern reduces fibrin sheath formation resulting from platelet activation. Representative images of
immunostained fibrinogen on (a) unpatterned, (b) +3SK2x2 and (c) -3SK2x2 TPU surfaces. Quantification of fluorescent images revealed that both
Sharklet micropatterns significantly reduce fibrinogen area coverage compared to unpatterned controls. Scale bar, 50 μm.
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controlling bacterial interaction for several medical de-
vice applications (e.g. urinary catheter and endotracheal
tubes) [32,33], but has yet to be evaluated for effective-
ness in a vascular environment and in a TPU material
that is predominately used for vascular access devices.
This study is the first of its kind to demonstrate the abil-
ity for an ordered micropattern, specifically the Sharklet
micropattern, to reduce S. aureus colonization after ex-
posure to whole blood (Table 1). This study also pre-
sents the first ordered micropattern embossed in TPU to
show performance against several CVC fouling agents,
i.e., bacterial colonization, platelet adhesion and fibrin
sheath formation (Figures 2, 3, 4 and Table 1).
This study demonstrates that not only do fewer plate-
lets adhere to the Sharklet micropattern, but there is
also significantly less platelet activation resulting in fi-
brin sheath formation (Figures 3, 4). Complex fibrin net-
works are a clinically relevant outcome of platelet adhesion
and activation, often leading to CVC occlusion or clots
that cause thromboembolisms [14,22]. These fibrin net-
works have been shown to facilitate microbial colonization
and correlate with CRBSIs that occur in the clinic
[20,22,24-27]. This study shows that the Sharklet micropat-
tern can individually reduce bacterial colonization in a sim-
ulated vascular environment and reduce fibrin sheath
formation that can enhance microbial colonization, thereby
functioning through a dual approach to potentially limit
infections.
Anti-adhesive or anti-biofilm surface alterations may
become competitive anti-infective solutions in the near
future as the demand increases for alternative approaches
[59,60]. Non-wetting topographies, like the Sharklet
micropattern, maintain air pockets among features that
limit microorganism interaction and provide energetically
unstable surfaces for bio-adhesion [37,61]. These surface
structures create hydrophobic effects with enhanced liquid
pinning/slipping to prevent biofouling [35,62]. For CVC
biomaterials, the combined effect of reduced microbial
burden (Table 1), smaller microbial aggregates (Figure 2),and reduced fibrin sheath formation (Figure 4) would
likely allow for improved immune clearance without
the need for multi-log kill effects achieved through
antimicrobials.
The Sharklet micropattern with protruding features
(+3SK2×2) showed improved performance against plate-
let adhesion and activation when compared to the micro-
pattern with recessed features (−3SK2×2) (Figures 3, 4).
Future work will evaluate feature size and spacing required
to achieve optimal boundary layer slip conditions for im-
proved hydrodynamics based on contact line pinning/slip-
ping [63]. It is anticipated that after pattern optimization
and manufacturing scale up, a CVC with the Sharklet
micropattern will demonstrate reduced CRBSI and CRT
rates through preclinical and clinical studies.
Conclusions
The Sharklet micropattern reduces S. aureus and S. epi-
dermidis colonization after exposure to a simulated
vascular environment by 70% or greater (p < 0.05) when
compared to smooth unpatterned controls. This micro-
pattern similarly reduces platelet adhesion and fibrin
sheath formation by approximately 80% (p < 0.05). Com-
bined, these results suggest that the Sharklet micropattern
implemented onto CVC surfaces will provide clinicians
with a non-eluting and non-toxic technology that inhibits
the mechanisms that lead to CRBSIs and CRTs.
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